28-Mar-2024
Benzinga (Mon, 25-Mar 2:44 PM ET)
What's Going On With Ocugen (OCGN) Shares?
Benzinga (Mon, 25-Mar 10:47 AM ET)
Ocugen, Inc. Appoints Huma Qamar, MD, MPH as Chief Medical Officer
Globe Newswire (Mon, 18-Mar 6:30 AM ET)
Globe Newswire (Wed, 13-Mar 8:00 AM ET)
Ocugen to Present at Investing in Cures Summit
Globe Newswire (Wed, 6-Mar 7:30 AM ET)
Ocugen Clinical Showcase Webcast Now Available
Globe Newswire (Wed, 28-Feb 8:00 AM ET)
Ocugen Chairman and CEO to present at Abu Dhabi Family Office Summit
Globe Newswire (Mon, 26-Feb 8:30 AM ET)
Globe Newswire (Thu, 22-Feb 4:05 PM ET)
Ocugen to Present at 2024 BIO CEO & Investor Conference
Globe Newswire (Wed, 21-Feb 4:05 PM ET)
Ocugen to Host Clinical Showcase in New York City on Wednesday, February 21, 2024
Globe Newswire (Wed, 14-Feb 7:30 AM ET)
Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. The breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug one to many and novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema and diabetic retinopathy. The company is co-developing Bharat Biotech's COVAXIN vaccine candidate for COVID-19 in the U.S. and Canadian markets.
Ocugen trades on the NASDAQ stock market under the symbol OCGN.
As of March 28, 2024, OCGN stock price declined to $1.64 with 8,828,199 million shares trading.
OCGN has a beta of 0.83, meaning it tends to be less sensitive to market movements. OCGN has a correlation of 0.01 to the broad based SPY ETF.
OCGN has a market cap of $420.55 million. This is considered a Small Cap stock.
In the last 3 years, OCGN stock traded as high as $17.65 and as low as $.35.
The top ETF exchange traded funds that OCGN belongs to (by Net Assets): VTI, VXF, VHT, GERM, BTEC.
OCGN has outperformed the market in the last year with a price return of +85.0% while the SPY ETF gained +33.6%. OCGN has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +203.7% and +57.7%, respectively, while the SPY returned +10.1% and +1.7%, respectively.
OCGN support price is $1.63 and resistance is $1.93 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that OCGN stock will trade within this expected range on the day.